泽璟制药已于2020年1月登陆科创板，证券代码：688266.SH，截至1月5日收盘，公司股价为96.99元/股，市值为256.7 亿元。 在经历了近4个月的阴跌之后，今天创新药板块终于再度爆发，港股创新药ETF涨超5%，昭衍新药、三生制药、信达 生物、百济神州等个股大涨。 消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进行"大规模生 产"。A股上演映射行情，三博脑科、美好医疗、翔宇医疗、伟思医疗、爱朋医疗等纷纷录得20cm涨停。 次新股英硅智能今日公告，已与全球独立制药公司施维雅（Servier）达成了一项总金额达8.88亿美元的研发合作。 此外，泽璟制药于2025年12月31日公告达成BD，将其CD3×DLL3三特异性抗体(ZG006)授权给艾伯维，泽璟将获得1亿 美元的首付款，以及最高可超11亿美元的里程碑付款。 与此同时，泽璟制药也正在冲击港股IPO。 格隆汇获悉，苏州泽璟生物制药股份有限公司（简称：泽璟制药）于2025年12月19日递表港交所，由中金公司担任保 荐人。 01 总部位于江苏昆山，已有三款产品上市 泽璟制药成立于2009年，2019 ...

泽璟制药的产品组合及管线涵盖已上市药物、后期临床候选药物及处于创新前沿的早期发现项目。目 前，泽璟制药拥有三款已上市药物：泽普生为中国首款本土研发用于晚期肝癌一线治疗的小分子多靶点 药物；泽普平为中国首款本土研发用于治疗骨髓纤维化的创新型JAK抑制剂；泽普凝为中国唯一采用重 组DNA技术研发并成功商业化的重组人凝血酶。 泽璟制药向港交所主板提交上市申请，中金公司为其独家保荐人。招股书显示，泽璟生物是一家综合性 生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，战略聚焦于肿瘤学、自身 免疫性疾病、止血/血液病三大治疗领域。 ...

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor, indicating its intent to expand its capital base for further development in the biopharmaceutical sector [1] Group 1: Company Overview - Zelgen Biopharmaceutical is a comprehensive biopharmaceutical company focused on the discovery, research and development, and commercialization of innovative small molecules and biological agents [1] - The company strategically focuses on three therapeutic areas: oncology, autoimmune diseases, and hemostasis/blood disorders [1] Group 2: Product Portfolio - Zelgen Biopharmaceutical has a product portfolio that includes marketed drugs, late-stage clinical candidates, and early-stage innovative discovery projects [1] - The company currently has three marketed drugs: - Zepu Sheng, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China - Zepu Ping, the first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis - Zepu Ning, the only recombinant human thrombin developed and successfully commercialized using recombinant DNA technology in China [1]

智通财经AIP较恐，据港交所12月19日披露，苏州泽璟生物制药股份有限公司(简称：泽璟制药)(688266.SH)向港交所主板提交上市申请，中金公司为其 独家保荐人。招股书显示，泽璟生物是一家综合性生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，战略聚焦于肿瘤学、自 身免疫性疾病、止血/血液病三大治疗领域。泽璟制药的产品组合及管线涵盖已上市药物、后期临床候选药物及处于创新前沿的早期发现项目。目前 泽璟制药拥有三款已上市药物：泽普生为中国首款本土研发用于晚期肝癌一线治疗的小分子多靶点药物：泽普平为中国首款本土研发用于治疗骨髓纤维 化的创新型JAK抑制剂；泽普凝为中国唯一采用重组DNA技术研发并成功商业化的重组人凝血酶。 視乎「編纂」行使與否而定） 最高[編纂] : 每股H股[編纂]港元,另加1.0%經紀 佣金、0.00015% 會財局交易徵費、 0.0027%證監會交易徵費及0.00565% 聯交所交易費(須於申請時以港元 獨家保薦人 ·[編纂] CICC中金公司 Suzhou Zelgen Biopharmaceuticals Co., Ltd. 蘇 州 澤 環 生 物 製 藥 股 份 有 ...

獨家保薦人 ·[編纂] CICC中金公司 「編纂]項下的[編纂]數目 : 「編纂]股Ｈ股(視乎[編纂] 行使與否而定) 「編纂]數目 「編纂]股H股(可予重新分配) : [編纂]數目 「編纂]股H股(可予重新分配及 . 視乎「編纂」行使與否而定） 每股H股[編纂]港元,另加1.0%經紀 最高[編纂] : 佣金、0.00015% 會財局交易徵費、 0.0027%證監會交易徵費及0.00565% 聯交所交易費(須於申請時以港元 繳足,多繳股款可予退還) 每股H股人民幣1.00元 画值 : [編纂] : [編纂] (於中華人民共和國註冊成立的股份有限公司) [編纂] 据港交所12月19日披露，苏州泽璟生物制药股份有限公司(简称：泽璟制药)(688266.SH)向港交所主板提交上市申请，中金公司为其独家保荐人。招股书 显示，泽璟生物是一家综合性生物制药企业，专注于创新型小分子及生物制剂疗法的发现。研发及商业化，战略聚焦于肿瘤学、自身免疫性疾病、止 血血液病三大治疗领域。泽璟制药的产品组合及管线涵盖已上市药物、后期临床候选药物及处于创新前沿的早期发现项目，目前，泽璟制药拥有三款 已上市药物：泽普生为中国首款本土研发用于 ...

Core Viewpoint - Suzhou Zejing Biopharmaceutical Co., Ltd. announced that its self-developed drug, JAK inhibitor Jikaxitinib (brand name: Zepuping), has received approval for marketing in China, targeting specific types of myelofibrosis in adult patients [1][2][3] Drug Basic Information - Drug Name: Jikaxitinib - Dosage Form: Tablet - Specification: 50mg - Marketing Authorization Holder: Suzhou Zejing Biopharmaceutical Co., Ltd. - Indications: For adult patients with intermediate or high-risk primary myelofibrosis (PMF), secondary myelofibrosis due to polycythemia vera (PPV-MF), and secondary myelofibrosis due to primary thrombocythemia (PET-MF), treating disease-related splenomegaly or symptoms [1][2] Drug Mechanism and Clinical Trials - Jikaxitinib is a novel JAK inhibitor that works by inhibiting the activity of JAK1, JAK2, JAK3, and TYK2, blocking the JAK-STAT signaling pathway to reduce inflammation and splenomegaly [2] - The approval is based on a Phase III clinical trial showing that 72.3% of patients had a ≥35% reduction in spleen volume after 24 weeks of treatment [3] - Other clinical trials indicated good safety and tolerability profiles for Jikaxitinib in the target patient population [3] Market Potential and Competitive Landscape - The annual incidence of myelofibrosis in China is approximately 60,000 new patients, with a total patient population exceeding 200,000 [5] - The market size for myelofibrosis drugs in China was 1.73 billion yuan in 2020, projected to grow to 2.93 billion yuan by 2025 and 3.30 billion yuan by 2030 [5] - Currently, the only approved targeted drug for treating intermediate and high-risk myelofibrosis in China is the imported drug Ruxolitinib, which had a global sales figure of approximately 4.9 billion USD in 2024 [5] Regulatory and Clinical Guidelines - Jikaxitinib has been included in the 2024 CSCO guidelines as a first-line treatment for myelofibrosis-related anemia and is recommended for second-line and advanced treatment [4] - The drug is also undergoing clinical trials for other immune-inflammatory diseases, including atopic dermatitis and ankylosing spondylitis [4]